Sarine Technologies Ltd. (SGX:U77)

Ligand Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	24.8	18.23	22.35	25.31	27.36	21.08
Short-Term Investments	2.55	8.07	0.63	10.68	9.06	6.3
Cash & Short-Term Investments	27.34	26.3	22.99	35.99	36.41	27.38
Cash Growth	2.73%	14.42%	-36.14%	-1.16%	32.97%	-7.09%
Receivables	8.19	9.2	14.65	21.48	23.06	21.97
Inventory	5.95	6.73	10.52	6.86	7.28	6.25
Prepaid Expenses	-	0.73	0.72	0.84	0.98	0.71
Other Current Assets	2.14	2.27	0.67	1.66	0.62	1.05
Total Current Assets	43.62	45.23	49.54	66.82	68.36	57.36
Property, Plant & Equipment	9.79	11.14	17.67	14.35	16.07	17.33
Goodwill	-	4.28	4.94	1.87	1.87	1.87
Other Intangible Assets	7.55	1.79	2.15	0	0.07	0.26
Long-Term Accounts Receivable	0.97	1.74	0.57	1.01	0.7	0.84
Long-Term Deferred Tax Assets	0.45	0.59	0.57	0.5	0.57	0.6
Long-Term Deferred Charges	-	0.98	0.05	0.18	0.31	0.43
Other Long-Term Assets	8.09	6.16	1.1	0.5	0.5	1.17
Total Assets	70.47	71.91	76.6	85.23	88.44	79.87
Accounts Payable	1.35	1.44	1.78	3.22	2.32	1.87
Accrued Expenses	-	4.06	3.62	5.4	5.72	3.82
Short-Term Debt	-	-	-	-	-	0.28
Current Portion of Leases	1.06	1.33	1.24	0.81	0.97	1.02
Current Income Taxes Payable	0.16	0.16	0.05	1.77	1.5	1.08
Current Unearned Revenue	-	1.28	1.64	1.18	1.32	0.99
Other Current Liabilities	6.06	0.75	0.68	2	1.03	1.38
Total Current Liabilities	8.63	9.02	9.01	14.38	12.87	10.45
Long-Term Debt	-	-	-	-	-	3.14
Long-Term Leases	3.19	4.17	5.39	3.56	4.74	5.34
Other Long-Term Liabilities	1.39	1.15	1.73	-	-	-
Total Liabilities	13.21	14.46	16.28	18.13	17.89	19.18
Additional Paid-In Capital	35.48	35.4	35.26	34.49	34.01	33.15
Retained Earnings	32.83	32.99	34.49	41.65	43.37	33.93
Treasury Stock	-6.63	-6.5	-5.18	-4.83	-3.94	-3.69
Comprehensive Income & Other	-4.42	-4.44	-4.25	-4.22	-2.9	-2.7
Shareholders' Equity	57.26	57.45	60.32	67.1	70.55	60.69
Total Liabilities & Equity	70.47	71.91	76.6	85.23	88.44	79.87
Total Debt	4.25	5.49	6.63	4.37	5.72	9.79
Net Cash (Debt)	23.09	20.81	16.35	31.62	30.7	17.6
Net Cash Growth	11.72%	27.25%	-48.29%	3.02%	74.45%	-21.61%
Net Cash Per Share	0.07	0.06	0.05	0.09	0.09	0.05
Filing Date Shares Outstanding	341.37	341.84	343.66	348.94	351.09	349.83
Total Common Shares Outstanding	341.37	342.13	347.74	348.94	351.09	349.83
Working Capital	34.99	36.21	40.53	52.44	55.49	46.91
Book Value Per Share	0.17	0.17	0.17	0.19	0.20	0.17
Tangible Book Value	49.71	51.38	53.22	65.22	68.61	58.56
Tangible Book Value Per Share	0.15	0.15	0.15	0.19	0.20	0.17
Buildings	-	7.4	13.87	13.42	14.06	14.14
Machinery	-	14.83	15.17	13.72	13.56	13.44

Source: S&P Global Market Intelligence. Standard template. Financial Sources.